Concord Biotech Ltd (CONCORDBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10038977,
    "name": "Concord Biotech",
    "stock_name": "Concord Biotech",
    "full_name": "Concord Biotech Ltd",
    "name_url": "stocks-analysis/concord-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,162.55",
    "chg": 55.45,
    "chgp": "5.01%",
    "dir": 1,
    "prev_price": "1,107.10",
    "mcapval": "12,011.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543960,
    "symbol": "CONCORDBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE338H01029",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.47 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/concord-biotech-10038977-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-downgraded-to-strong-sell-amid-weak-financial-and-technical-indicators-3733005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_mojoScore_3733005.png",
        "date": "2025-11-27 10:06:45",
        "description": "Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators."
      },
      {
        "title": "Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-biotech-q2-fy26-sharp-profit-decline-amid-revenue-volatility-raises-red-flags-3718506",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_quaterlyResult_3718506.png",
        "date": "2025-11-15 11:01:09",
        "description": "Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points."
      },
      {
        "title": "How has been the historical performance of Concord Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-biotech-3699794",
        "imagepath": "",
        "date": "2025-11-13 23:50:41",
        "description": "Answer:\nThe historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.\n\nBreakdown:\nConcord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t..."
      }
    ],
    "total": 329,
    "sid": "10038977",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/concord-biotech-10038977"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "06-Jan-2026",
      "details": "Enclosed herewith the certificate under Regulation 74(5) of the SEBI (DP) Regulations2018 for the quarter ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Dec-2025",
      "details": "Intimation of Trading window closure from 1st January2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer",
      "datetime": "24-Dec-2025",
      "details": "Ms. Hina Patel has tendered her resignation from the post of Company Secretary and Compliance Officer w.e.f 21/01/2026 after close of working hours.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Concord Biotech Ltd has declared <strong>1070%</strong> dividend, ex-date: 03 Sep 25",
          "dt": "2025-09-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends

2025-11-27 10:06:45

Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators.

Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags

2025-11-15 11:01:09

Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points.

How has been the historical performance of Concord Biotech?

2025-11-13 23:50:41

Answer: The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years. Breakdown: Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t...

View All News